engleski

PAX8-PPARy Oncogene in Follicular Thyroid Tumors: RT-PCR and Immunohistochemical Analyses

US-guided fine needle aspiration cytology is currently the best diagnostic tool for thyroid nodules. However, it is not sensitive and specific enough for differentiating between benign and malignant follicular tumors. A potentially useful marker for this differentiation is the PAX-PPARy rearrangement, identified in follicular thyroid carcinomas, but not in follicular adenomas or other types of thyroid tumors. The study included 62 patients with follicular or Hurthle cell tumors. Gene expression was determined by reverse transcription-polymerase chain reaction (RT-PCR) from paraffin embedded tissues, and PCR products were checked using the agarose gel electrophoresis. The immunohistochemical analysis was performed on archive paraffin embedded tissues with the monoclonal PPARy antibody. The statistical analysis has indicated that neither the expression of PAX8-PPARy mRNA, nor the immunohistochemical analysis with the PPARy antibody correlate with the pathohystological diagnosis. The oncogene PAX8-PPARy has not met the expectations as a reliable tumor marker for differentiation between benign and malignant thyroid tumors, which makes the only reliable histological criteria-capsular and vascular invasion.

follicular thyroid tumors; PAX8-PPARy rearrangement; RT-PCR; immunohistochemistry

nije evidentirano